As single agent therapies, the efficacy of PI3K/AKT/mTOR inhibitors in the treatment of a variety of cancers has generally not been satisfactory and phase III clinical trials have not been reported yet in patients with ovarian cancer [92,93,94,95,96]. This evidence concerns the gene PIK3CA and ovarian cancer.